May 21, 2019
Seattle Genetics appoints new Chief Commercial Officer
Seattle Genetics has announced the appointment ofRobin G. Taylor, M.B.A., Ph.D., as Chief Commercial Officer
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
May 21, 2019
AmerisourceBergen’s Xcenda acquires Dymaxium
Xcenda,a part of AmerisourceBergen, today announced the acquisition ofDymaxium, a trusted market access partner specializing in the exchangeof evidence and information between payers and life science companiesthrough its FormularyDecisions.com® platform.
May 21, 2019
Debiopharm enrolls patient to test treatment in solid tumors
Debiopharm has enrolled first patient in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors.
May 21, 2019
Design contract for UK’s first Vaccines Manufacturing Innovation Centre won by WHP
The development of the UK’s first dedicated Vaccines Manufacturing Innovation Centre (VMIC) has moved a step closer with the contract to design an advanced array of laboratory and production facilities within a ‘cleanroom wrap’ environment being awarded to WHP, the company has said in a statement.
May 21, 2019
US Breast Cancer Drug Market 2019-2025 Opportunity: $ 20 Billion
DUBLIN–(BUSINESS WIRE)–The “US Breast Cancer Drug Market, Price, Dosage & Clinical Pipeline Insight 2025” drug pipelines has been added to…
May 20, 2019
PharmaCyte Biotech Proceeding with GMP Production of Pancreatic Cancer Product After Successful Changes to Manufacturing Process
PharmaCyte Biotech Proceeding with GMP Production of Pancreatic Cancer Product After Successful Changes to Manufacturing Process
May 20, 2019
Merck Keytruda in triple-negative breast cancer (TNBC) study misses its pre-specified primary endpoint of superioroverall survival (OS) compared to chemotherapy
The KEYTRUDA breast cancer clinical development program encompassesseveral internal and external collaborative studies, including threeongoing registration-enabling studies in TNBC.
May 20, 2019
Clovis Oncology’s Rubraca Rubraca passes over placebo from a patient perspective in Advanced Ovarian Cancer
Quality-adjusted progression free survival (QA-PFS) andquality-adjusted time without cancer related symptoms or toxicity(Q-TWiST) demonstrate the benefit of Rubraca maintenance treatment overplacebo from a patient perspective
May 20, 2019
Ocular Therapeutix’s glaucoma treatment fails to meet primary endpoint in P3 trial, for gets statistically significant reduction of intraocular pressure versus placebo
OTX-TP failed to meet primary endpoint but achieved statisticallysignificant reduction of intraocular pressure versus placebo at eight ofthe nine pre-specified time points
May 20, 2019
Verona Pharma finds more symptoms benefits from ensifentrine in COPD patients
Verona Pharma posted Monday expanded analysis to positive results from March, from from findings from its chronic obstructive pulmonary disease (“COPD”) clinical trial program with lead product candidate, ensifentrine (RPL554). Positive results from the 4-week, 400-patient Phase 2b study were initially reported in March 2018.